NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

The Kraft Heinz Company (NASDAQ: KHC)
Class Period: May 4, 2017 - February 21, 2019
Deadline: April 25, 2019
For more info: www.bgandg.com/khc

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Kraft’s internal controls, specifically with respect to its procurement area, were inadequate; (2) Kraft would be forced to write down a significant amount of goodwill and certain intangible assets in its Kraft natural cheese business, its Oscar Mayer cold cuts business, and its Canada retail business due to supply chain issues; (3) Kraft failed to advise investors of the foregoing issues; and (4) as a result, Kraft’s public statements were materially false and misleading at all relevant times.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
Class Period: August 4, 2016 - January 31, 2019
Deadline: April 26, 2019
For more info: www.bgandg.com/aveo

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in the June 2013; (2) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (3) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (4) as a result, AVEO’s public statements were materially false and misleading at all relevant times. 

CVS Health Corporation (NYSE: CVS)
Class Period: May 21, 2015 - February 20, 2019
Deadline: April 26, 2019
For more info: www.bgandg.com/cvs

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) CVS Health’s financial condition and expected earnings were deteriorating as a result of rising costs and poor results associated with the Omnicare Acquisition; and (2) as a result, CVS Health’s public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.